1. Benefits and Harms of Phosphate Binders in CKD: A Systematic Review of Randomized Controlled Trials 
Sankar D. Navaneethan, MD, MPH, Suetonia C. Palmer, MBChB, Jonathan C. Craig, MBChB, PhD, Grahame J. Elder, PhD, Giovanni F.M. Strippoli, MD, PhD, MPH, MM 
American Journal of Kidney Diseases 
Volume 54, Issue 4, Pages (October 2009)
DOI: /j.ajkd
Copyright © 2009 National Kidney Foundation, Inc. Terms and Conditions

2. Figure 1
Literature search flow diagram. Reasons for exclusions and number of trials reporting each outcome are shown.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2009 National Kidney Foundation, Inc. Terms and Conditions

3. Figure 2
Effect of sevelamer compared with calcium salts on all-cause mortality in people with chronic kidney disease. Abbreviation: CI, confidence interval.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2009 National Kidney Foundation, Inc. Terms and Conditions

4. Figure 3
Effect of phosphate binders on end-of-treatment serum phosphorus concentration in people with chronic kidney disease. Conversion factor for phosphorus in mg/dL to mmol/L, × Abbreviation: CI, confidence interval.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2009 National Kidney Foundation, Inc. Terms and Conditions

5. Figure 4
Effect of phosphate binders on end-of-treatment parathyroid hormone concentration (pg/mL) in people with chronic kidney disease. Parathyroid hormone in pg/mL and ng/L requires no conversion. Abbreviation: CI, confidence interval.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2009 National Kidney Foundation, Inc. Terms and Conditions